Sangamo BioSciences Announces Second Quarter 2014 Conference Call And Webcast

Sangamo BioSciences Announces Second Quarter 2014 Conference Call And Webcast

PR Newswire

RICHMOND, Calif., July 16, 2014

RICHMOND, Calif., July 16, 2014 /PRNewswire/ --Sangamo BioSciences, Inc.
(NASDAQ: SGMO) today announced that the company will release its second
quarter 2014 financial results after the market closes on Wednesday, July 23,
2014. The press release will be followed by a conference call at 5:00 p.m. ET,
which will be open to the public via telephone and webcast. During the
conference call, the company will review the quarter's financial results and
discuss other new business developments.

Sangamo BioSciences, Inc.

The conference call dial-in numbers are (877) 377-7553 for domestic callers
and (678) 894-3968 for international callers. The conference ID number for the
call is 69820610. Participants may access the live webcast via a link on the
Sangamo BioSciences website in the Investors section under Events and
Presentations. For those unable to listen in at the designated time, a
conference call replay will be available for one week following the conference
call, from approximately 8:00 p.m. ET on July 23, 2014 to 11:59 p.m. ET on
July 30, 2014. The conference call replay numbers for domestic and
international callers are (855) 859-2056 and (404) 537-3406, respectively. The
conference ID number for the replay is 69820610.

About Sangamo

Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures^™ for
monogenic and infectious diseases by deploying its novel DNA-binding protein
technology platform in therapeutic gene regulation and genome editing. The
Company has ongoing Phase 2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic^® for the treatment of HIV/AIDS (SB-728-T)
and NGF-AAV for Alzheimers disease (CERE-110). Sangamo's other therapeutic
programs are focused on monogenic and rare diseases. The company has formed a
strategic collaboration with Shire International GmbH to develop therapeutics
for hemophilia, Huntington's disease and other monogenic diseases, and with
Biogen Idec for hemoglobinopathies, such as sickle cell disease and
beta-thalassemia. It has also established strategic partnerships with
companies in non-therapeutic applications of its technology, including Dow
AgroSciences and Sigma-Aldrich Corporation. For more information about
Sangamo, visit the Company's website at

ZFP Therapeutic^® is a registered trademark of Sangamo BioSciences, Inc.


SOURCE Sangamo BioSciences, Inc.

Contact: Sangamo BioSciences, Inc., Elizabeth Wolffe, Ph.D., 510-970-6000,
x271, or Varant Shirvanian, (510) 970-6000, x205
Press spacebar to pause and continue. Press esc to stop.